Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of High-Density Lipoprotein in Obesity Study

This study has been terminated.
(Investigator left institution)
Information provided by (Responsible Party):
The Cleveland Clinic Identifier:
First received: May 20, 2009
Last updated: April 11, 2017
Last verified: April 2017
Obesity is associated with an impaired functioning HDL (good cholesterol) resulting in an acceleration in the development of atherosclerosis. This study will evaluate HDL functionality in patients with BMI (Body Mass Index) 20 - 25 and BMI >30


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of High-Density Lipoprotein in Obesity Study

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • To determine whether the functional activity of HDL is impaired in the setting of obesity [ Time Frame: Within 2 weeks of enrollment ]

Secondary Outcome Measures:
  • To determine whether HDL is more susceptible to oxidative modification ex-vivo in obese patients by mass spectrometry [ Time Frame: Within 2 weeks of enrollment ]

Biospecimen Retention:   Samples Without DNA
Plasma and serum will be collected

Enrollment: 77
Actual Study Start Date: June 2009
Study Completion Date: March 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
BMI 20-25 kg/m2
BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)

Detailed Description:
This study will determine if the protective function of high-density lipoprotein (HDL) is impaired in obese patients and will help to enhance cardiovascular risk prediction. Carotid intima-media thickness (cIMT) will be captured as a means of assessing early vascular changes associated with low HDL levels in obesity. A novel measurement for clinical correlation has also been introduced called carotid extra-medial thickness (cEMT) which will be compared to cIMT in this obese population.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study population will be selected from Cleveland Clinic outpatient departments

Inclusion Criteria:

  • Group 1:

    • Age 20-80
    • English speaking
    • BMI 20-25 kg/m2
  • Group 2:

    • Age 20-80
    • English speaking
    • BMI > 30 kg/m2
    • TG > 150 and
    • HDL > 50 (females) >40 (Males)
  • Group 3:

    • Age 20-80
    • English speaking
    • BMI > 30 kg/m2
    • TG > 150 and
    • HDL < 50 (females) < 40 (males)

Exclusion Criteria:

  • Self-reported history of:

    • Diabetes mellitus
    • Any previous lipid therapy within the last three months
    • Macrovascular events including TIA, stroke, myocardial infarction, heart failure, claudication, or known peripheral vascular disease
    • Current pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00912236

United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Principal Investigator: Stephen Nicholls, MBBS, PhD The Cleveland Clinic
  More Information

Responsible Party: The Cleveland Clinic Identifier: NCT00912236     History of Changes
Other Study ID Numbers: 09-302
Study First Received: May 20, 2009
Last Updated: April 11, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by The Cleveland Clinic:
HDL functionality

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on April 26, 2017